key: cord-0285576-x67xt6u1 authors: Ye, Chengjin; Martinez-Sobrido, Luis title: Using a reverse genetics system to generate recombinant SARS-CoV-2 expressing robust levels of reporter genes date: 2022-05-23 journal: bioRxiv DOI: 10.1101/2022.05.21.492922 sha: eaddab0f82b7b6fbc2f68a1efe021a1358f8584b doc_id: 285576 cord_uid: x67xt6u1 Reporter-expressing recombinant virus represents an excellent option and a powerful tool to investigate, among others, viral infection, pathogenicity, and transmission, as well as to identify therapeutic compounds that inhibit viral infection and prophylactic vaccines. To combat the still ongoing coronavirus disease 2019 (COVID-19) pandemic, we have established a robust bacterial artificial chromosome (BAC)-based reverse genetics (RG) system to rapidly generate recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) to study the contribution of viral proteins in viral pathogenesis. In addition, we have also engineered reporter-expressing recombinant viruses in which we place the reporter genes upstream of the viral nucleocapsid (N) gene to promote high levels of reporter gene expression that facilitates the study of SARS-CoV-2 in vitro and in vivo. Although successful, the genetic manipulation of the BAC containing the entire SARS-CoV-2 genome of ∼30,000 nucleotides, is challenging. Herein, we depict the technical details to engineer rSARS-CoV-2 expressing reporter genes using the BAC-based RG approach. We describe i) assembly of the full-length (FL) SARS-CoV-2 genome sequences into the empty pBeloBAC, ii) verification of the pBeloBAC-FL, iii) cloning of a Venus reporter gene into the pBeloBAC-FL, and iv) recovery of the Venus-expressing rSARS-CoV-2. By following this protocol, researchers with basic molecular biology and gene engineering techniques knowledge will be able to generate wild-type and reporter-expressing rSARS-CoV-2. l Triton X-100 (Sigma-Aldrich, catalog #: X100-500ML The 2% agar will solidify after cooling down. Microwave for 1-3 min to 397 completely melt before using in the plaque assays. Blocking solution 408 Add 77 mL of 35% BSA solution to 1 L of PBS and mix completely. Store at 4°C. The blocking solution is also used to dilute primary and secondary antibodies. and BstBI work at 55°C and 65°C, respectively. (i) Prepare five 0.6% agarose gels that are 10-cm long and with 10-mm-wide 463 loading wells. (ii) Weigh 0.6 g agarose powder and dispense into a conical 250 mL glass flask. Add 100 mL 1x TAE buffer. (iii) After gently mixing, microwave for 3 min to completely melt the agarose. (iv) Add 10 μL of 10,000x GelRed to the 0.6% agarose solution after the gel's 468 temperature has cooled down to 50°C. Mix thoroughly. (v) Pour the mixture into a gel casting tray which has been fitted with a gel (xii) Air-dry the sample until a white pellet is visualized. CAUTION It takes ~20 505 min, it may lead to decreased elution efficiency if it is overdried. (xiii) Add 30 µL nuclease-free water to resuspend the pellet by flicking 5 times. Incubate the tube at 50°C for 10 min. (xiv) Centrifuge for 30 s, carefully pipet the supernatant into a clean 1.5 mL tube. is shown in Fig. 2b . The PCR-positive clone is further confirmed by sanger 626 sequencing using the CMV/F and bGH/R primers ( band from the gel as described in step 6. Table 4 . Nuclease-free water 33 µL 10x Buffer without Table 4 . Nuclease-free water 32 µL 10x Buffer without Nuclease-free water Up to 100 µL (iv) Heat shock the cells in the mixture at exactly 42°C for exactly 30 seconds. (v) Immediately put the tubes back on ice for 5 min. (iii) Add 500 µL Solution II and invert gently to obtain a clear lysate. (iv) Add 700 µL ice-cold N3 buffer and mix gently by inverting tube 10 times 792 until a white precipitate forms, and incubate the tube on ice for 10 min. (v) Spin down the precipitate by centrifugating at 15,000 g at 4°C for 10 min. Fig. 6b (left column) Sinai for providing the 1C7C7 monoclonal antibody. We are thankful also to Dr Tracey Baas for criticizing reading and editing this manuscript. 965 966 REFERENCES 971 Nowcasting and forecasting the 54 Rapid reconstruction of SARS-CoV-2 using a synthetic 1008 genomics platform Recovery of a neurovirulent human coronavirus OC43 1011 from an infectious cDNA clone Engineering a Replication-Competent Engineering SARS-CoV-2 using a reverse genetic system and the pBeloBAC-FL backbone after BamHI and RsrII digestion to remove 1077 the parental F1 segment for subcloning of the F1/Venus-2A Colony PCR screening of pBeloBAC-FL/Venus-2A colonies Figure 6. Characterization of rSARS-CoV-2/Venus-2A Fluorescent (Venus) and IFA (N) confirmation of rSARS-CoV-2/Venus-2A 1082 rescue. rSARS-CoV-2/WT was included as an internal control Detection of fluorescent plaques formed by rSARS-CoV-2/Venus-2A under 1084 a ChemiDoc imaging system. Immunostaining with the N protein 1C7C7 MAb 1085 of the plaques formed by rSARS-CoV-2/Venus-2A and rSARS-CoV-2/WT